Company news

PTC Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results

February 16, 2020

PTC Therapeutics Announces First Publication of Real-World Data Showing Translarnaä (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy

February 2, 2020

PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy

November 24, 2019

PTC Therapeutics Launches A No-Cost Testing Program to Drive AADC Deficiency Patient Identification

November 17, 2019

PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

October 28, 2019

PTC Therapeutics Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvements

October 23, 2019

PTC Therapeutics Establishes Strategic Collaboration with Aldevron to Support GMP Plasmid Manufacturing

October 6, 2019

PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy

October 3, 2019

PTC Therapeutics Announces Pricing of Private Offering of Convertible Senior Notes

September 17, 2019

PTC Therapeutics Announces Proposed Public Offering of Common Stock

September 16, 2019

PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

August 5, 2019

PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics

June 30, 2019

PTC Provides Update on Translarna(TM) (ataluren) Application for Label Expansion

June 27, 2019

PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

June 6, 2019

PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update

May 1, 2019

Translarna(TM) (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy

April 28, 2019

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results

April 17, 2019

← Newer news releases

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 33 decks. Every deck is listed under its year.